MYL3
ENSG00000160808
Target class
Unclassified protein
Chromosome
3
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- MYL3
- Gene name
- Myosin light chain 3
- Gene symbol
- MYL3
- Protein name
- Myosin light chain 3 (Cardiac myosin light chain 1) (CMLC1) (Myosin light chain 1, slow-twitch muscle B/ventricular isoform) (MLC1SB) (Ventricular myosin alkali light chain) (Ventricular myosin light chain 1) (VLCl) (Ventricular/slow twitch myosin alkali light chain) (MLC-lV/sb)
- CMH8
- VLC1
- MLC1V
- MLC1SB
- Gene biotype
- Protein coding
- Gene family
- Myosin light chains, class 1
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 50
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 3,733.53
- Tissue specificity (Gini)
- 0.942
- Tissue specificity (tau)
- 0.994
- KEGG gene identifiers
- hsa:4634
- Reactome pathways
- R-HSA-390522
- Protein interaction confidence
- 0.87366
- Protein interaction partners
- 53
- End position
- 46885911
- Start position
- 46835109
- Chromosome
- 3
- Strand
- Reverse
- Mitochondria
- Nucleoli
- Tissue specificity (tau)
- 0.994105
- Expression inequality (Gini)
- 0.941801
Expression in transcripts per million
- Heart - Left Ventricle
- 3,733.53
- Muscle - Skeletal
- 803.26
- Heart - Atrial Appendage
- 131.1
- Kidney - Cortex
- 27.09
- Kidney - Medulla
- 13.16
Expression in transcripts per million
- Heart - Left Ventricle3,733.53
- Muscle - Skeletal803.26
- Heart - Atrial Appendage131.1
- Kidney - Cortex27.09
- Kidney - Medulla13.16
- Brain - Spinal cord (cervical c-1)10.88
- Cervix - Ectocervix8.84
- Cervix - Endocervix8.35
- Spleen7.91
- Brain - Substantia nigra7.66
- Lung6.54
- Brain - Hypothalamus6.04
- Adipose - Subcutaneous5.81
- Fallopian Tube5.78
- Brain - Hippocampus5.75
- Ovary5.39
- Adipose - Visceral (Omentum)5.35
- Brain - Anterior cingulate cortex (BA24)5.32
- Vagina5.04
- Brain - Amygdala4.93
- Uterus4.66
- Breast - Mammary Tissue4.57
- Brain - Cortex4.49
- Artery - Tibial4.35
- Esophagus - Gastroesophageal Junction4.29
And 29 more, listed on the interactive page.
- GO:0002026
- GO:0006942
- GO:0055010
- GO:0060048
- GO:0005829
- GO:0005859
- GO:0030017
- GO:0031672
- GO:0031674
- GO:0003785
- GO:0008307
Related records
Trials (65)
- A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
- A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers
- A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
- A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
- A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
- A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada
- A Study of CK-1827452 Infusion in Stable Heart Failure
- A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)
- A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
- A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
- A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
- A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
- A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
- A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
- A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
- A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
- A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
- A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
- A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Drugs (3)
- Danicamtiv Cardiac myosin activator
- Mavacamten Cardiac myosin inhibitor
- Omecamtiv mecarbil Cardiac myosin activator